Cellex Incorporated specializes in the development of advanced diagnostic technologies aimed at enhancing point-of-care (POC) testing for various human diseases. Among their key innovations is the Lateral Flow Chromatographic Immunoassay, a rapid and user-friendly diagnostic method that allows for the quick detection of specific substances in liquid samples. This technology is exemplified in their Cellex q Rapid Test and Lateral Flow Rapid Test products, which provide timely and accurate diagnoses for a range of conditions. Additionally, Cellex employs Real-Time PCR (qPCR) technology, a powerful molecular biology technique that quantifies specific DNA sequences in real time, enabling the detection of various diseases through their specialized qPCR instruments and reagents.

Another significant technology utilized by Cellex is the Homogeneous Biochemiluminescence Assay (HBA), which measures light emissions from biochemical reactions to deliver sensitive and precise testing results. This method is particularly effective for detecting diseases such as influenza. With a portfolio of over 50 diagnostic products, Cellex is committed to providing healthcare professionals with reliable tools for accurate diagnostics at the point of care, thereby contributing to improved patient outcomes and advancing the field of in vitro diagnostics (IVD).

United States

Cellex has developed a rapid test for IgG and IgM antibodies to SARS-CoV-2. The company hastests that detect antibodies to multiple kinds of pathogens including HIV, HCV, Syphilis, HSV, and also makes tests for diabetes.Cellex received emergency use authorization (EUA) for its COVID-19 antibody test from the FDA for qSARS-CoV-2 IgG/IgM Rapid Test in 3/2020

Cellex

Company Details